Polar Power Announces Reverse Stock Split
At the annual meeting of stockholders held on November 11, 2024, Polar Power’s stockholders granted authority to the Board of Directors (the “Board”) to effect, in its discretion prior to December 31, ...
Meta Platforms Inc. (META): An AI Stock Grabbing Investor Attention
The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and ...
Chinese self-driving firm Pony AI seeks up to $4.5 billion valuation in US IPO
Pony AI is seeking a valuation of up to $4.48 billion in its U.S. initial public offering, it said on Thursday, as the ...
China's Pony AI seeks up to $4.5 billion valuation in long-sought New York listing
(Reuters) -Pony AI is seeking a valuation of up to $4.48 billion in its U.S. initial public offering, it said on Thursday, as ...
Hollywood Favorite, Fatburger, Opens 10th Location in Texas
Beloved Burger Chain Continues to Sizzle in the Lone Star State with Latest San Antonio Area Opening LOS ANGELES, Nov. 14, 2024 (GLOBE ...
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally
According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectableCompany ...
Business Insider1d
Adaptimmune Reports Q3 2024 Financial and Business Updates
expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial ...
Business Insider2d
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Lete-cel is being investigated for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO (NCT03967223) trial in patients who received prior ...
Mission Produce to Participate in the Stephens Annual Investment Conference
The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's Investor Relations website at https://investors.missionproduce.com/.
Business Insider3d
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
Canterbury Park Reports Q3 Earnings and Development Progress
Canterbury Park Holding ( (CPHC) ) has released its Q3 earnings. Here is a breakdown of the information Canterbury Park Holding presented to ...